Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

Murakami, H; Tamura, T; Takahashi, T; Nokihara, H; Naito, T; Nakamura, Y; Nishio, K; Seki, Y; Sarashina, A; Shahidi, M; Yamamoto, N

Murakami, H; Tamura, T; Takahashi, T; Nokihara, H; Naito, T; Nakamura, Y; Nishio, K; Seki, Y; Sarashina, A; Shahidi, M; Yamamoto, N.

Affiliation

Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka 411-8777, Japan.

Cancer Chemother Pharmacol ; 69(4): 891-9, 2012 Apr.

Article in En | MEDLINE | ID: mdl-22071596

Subject(s)

Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; Protein Kinase Inhibitors/adverse effects; Protein Kinase Inhibitors/therapeutic use; Quinazolines/adverse effects; Quinazolines/therapeutic use; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Non-Small-Cell Lung/enzymology; Dose-Response Relationship, Drug; ErbB Receptors/antagonists & inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms/enzymology; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines/administration & dosage

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / Lung Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2012 Document type: Article Affiliation country: Japan Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google